For patients with bladder cancer, invisible blood in urine may aid diagnosis
the ONA take:
According to new research published in the British Journal of General Practice, invisible blood in the urine may be able to be used to diagnose bladder cancer. Researchers at the University of Exeter Medical School in Exeter, United Kingdom, identified over 26,000 patients from the Clinical Practice Research Datalink and found that one in 60 patients over the age of 60 who had invisible blood in their urine were later diagnosed with bladder cancer.
The best known indicator of bladder cancer is visible blood in urine. Identifying invisible blood could boost early detection of bladder cancer, thereby improving outcomes compared with those who are diagnosed late.
According to the National Cancer Institute, if diagnosed with stage 1 bladder cancer, a patient has an 88% 5-year survival rate, but if diagnosed with stage 4 cancer, the 5-year survival rate drops to 15%.
The American Cancer Society says that nearly 75,000 Americans will be diagnosed with bladder cancer and about 16,000 will die from the disease in 2014. Bladder cancer is about three times more likely in men than women and occurs mainly in older adults.
Invisible blood in the urine may be able to be used to diagnose bladder cancer.
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. Scientists at the University of Exeter Medical School found that one in 60 people over the age of 60 who had invisible blood in their urine (identified by their GP testing their urine) transpired to have bladder cancer.
The figure was around half those who had visible blood in their urine - the best known indicator of bladder cancer. However, it was still higher than figures for other potential symptoms of bladder cancer that warrant further investigation.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|